Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer and Genaissance eye individualised medicine:

This article was originally published in Clinica

Executive Summary

Bayer Diagnostics has formed a deal with Genaissance Pharmaceuticals to develop diagnostic tests for determining adverse drug response and efficacy response to existing drug classes and new drug products. Genaissance will apply its haplotype technology, HAP, to Bayer's clinical samples in order to identify diagnostic markers and therapeutic targets for individualised medicine. Bayer will receive exclusive rights to develop and market tests based on the results of the collaboration. Genaissance will receive royalties and rights to perform these tests in its CLIA-certified diagnostic laboratory. There are mutual royalty provisions for any drugs derived from the co-operation.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT060855

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel